NEW YORK – Grail shareholders have filed a complaint with the US District Court for the Northern District of California alleging that Grail and three of its executives violated federal securities laws ...

NEW YORK – A new European diagnostics network has been initiated to support the development of new tools for infectious disease detection and diagnosis. Called the Pan European One Health Network for ...

The firms will validate histopathology biomarkers related to bladder cancer using clinical data and tissue samples captured during cystoscopy.

The company recently submitted for publication data on a feline cancer assay, which could trigger a $5 million payment from a licensee.

The companies will initially offer C2N's PrecivityAD test in Argentina, Chile, Colombia, Dominican Republic, Ecuador, Jamaica, Mexico, Uruguay, and Venezuela.

Under the repurchase program, the company may repurchase shares through open market purchases, in privately negotiated transactions, or by other means.

Last week, readers were most interested in a story about ASCO's decision not to recommend the use of Grail's MCED test in light of NHS trial data.

NEW YORK – Bluejay Diagnostics announced on Tuesday definitive agreements for the purchase and sale of its stock and warrants that are expected to raise up to $23.6 million in gross proceeds. Acton, ...

Under the agreement, NDT has an exclusive worldwide license for diagnostic use of a panel of nine antibodies to different tau protein forms.

NEW YORK – Waters said Wednesday that it has received US Food and Drug Administration 510(k) approval for its automated BD Bactec FXI Culture System. According to Waters, clinical study data shows ...

NEW YORK – Tempus on Wednesday said that it is making its Paige Image Management System (IMS) open source for members of a newly formed digital pathology consortium, with Yale New Haven Hospital and ...